Literature DB >> 15965496

Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice.

Anne-Ulrike Trendelenburg1, Angelika Meyer, Jürgen Wess, Klaus Starke.   

Abstract

The muscarinic heteroreceptors modulating noradrenaline release in atria, urinary bladder and vas deferens were previously studied in mice in which the M(2) or the M(4) muscarinic receptor genes had been disrupted. These experiments showed that these tissues possessed both M(2) and non-M(2) heteroreceptors. The analysis was now extended to mice in which either the M(3), both the M(2) and the M(3), or both the M(2) and the M(4) genes had been disrupted (M(3)-knockout, M(2/3)-knockout and M(2/4)-knockout). Tissues were preincubated with (3)H-noradrenaline and then stimulated electrically (20 pulses per 50 Hz). In wild-type atria, carbachol (0.01-100 microM) decreased the electrically evoked tritium overflow by maximally 60-78%. The maximum inhibition of carbachol was reduced to 57% in M(3)-knockout and to 23% in M(2/4)-knockout atria. Strikingly, the effect of carbachol was abolished in M(2/3)-knockout atria. In wild-type bladder, carbachol (0.01-100 microM) reduced the evoked tritium overflow by maximally 57-71%. This effect remained unchanged in the M(3)-knockout, but was abolished in the M(2/4)-knockout bladder. In wild-type vas deferens, carbachol (0.01-100 microM) reduced the evoked tritium overflow by maximally 34-48%. The maximum inhibition of carbachol was reduced to 40% in the M(3)-knockout and to 18% in the M(2/4)-knockout vas deferens. We conclude that the postganglionic sympathetic axons of mouse atria possess M(2) and M(3), those of the urinary bladder M(2) and M(4), and those of the vas deferens M(2), M(3) and M(4) release-inhibiting muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965496      PMCID: PMC1576238          DOI: 10.1038/sj.bjp.0706297

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice.

Authors:  Weilie Zhang; Anthony S Basile; Jesus Gomeza; Laura A Volpicelli; Allan I Levey; Jürgen Wess
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

2.  Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice.

Authors:  Weilie Zhang; Masahisa Yamada; Jesus Gomeza; Anthony S Basile; Jürgen Wess
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

3.  Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice.

Authors:  Dinesh Gautam; Thomas S Heard; Yinghong Cui; Georgina Miller; Lanh Bloodworth; Jürgen Wess
Journal:  Mol Pharmacol       Date:  2004-08       Impact factor: 4.436

Review 4.  Presynaptic alpha-autoreceptors.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1987       Impact factor: 5.545

5.  Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice.

Authors:  Hongxia Zhou; Angelika Meyer; Klaus Starke; Jesus Gomeza; Jürgen Wess; Anne-Ulrike Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-12-18       Impact factor: 3.000

6.  Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.

Authors:  E T Tzavara; F P Bymaster; C C Felder; M Wade; J Gomeza; J Wess; D L McKinzie; G G Nomikos
Journal:  Mol Psychiatry       Date:  2003-07       Impact factor: 15.992

Review 7.  Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications.

Authors:  Jürgen Wess
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

8.  Heterogeneity of presynaptic muscarinic receptors mediating inhibition of sympathetic transmitter release: a study with M2- and M4-receptor-deficient mice.

Authors:  Anne-Ulrike Trendelenburg; Jesus Gomeza; Werner Klebroff; Hongxia Zhou; Jürgen Wess
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

9.  All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons.

Authors:  Anne-Ulrike Trendelenburg; Melanie Philipp; Angelika Meyer; Werner Klebroff; Lutz Hein; Klaus Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-11       Impact factor: 3.000

10.  Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice.

Authors:  Nicole Struckmann; Sandra Schwering; Silke Wiegand; Anja Gschnell; Masahisa Yamada; Wolfgang Kummer; Jürgen Wess; Rainer V Haberberger
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

View more
  8 in total

1.  Inhibition of transmitter release from rat sympathetic neurons via presynaptic M(1) muscarinic acetylcholine receptors.

Authors:  H Kubista; K Kosenburger; P Mahlknecht; H Drobny; S Boehm
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

Review 2.  Synthesis, trafficking, and localization of muscarinic acetylcholine receptors.

Authors:  Neil M Nathanson
Journal:  Pharmacol Ther       Date:  2008-05-16       Impact factor: 12.310

3.  Es kann die Spur von unseren Erdetagen--on pharmacologists and pharmacology.

Authors:  Klaus Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11       Impact factor: 3.000

4.  Decrease in heart adrenoceptor gene expression and receptor number as compensatory tool for preserved heart function and biological rhythm in M(2) KO animals.

Authors:  Jan Benes; Eva Varejkova; Vladimir Farar; Martina Novakova; Jaromir Myslivecek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-24       Impact factor: 3.000

5.  Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.

Authors:  Kirsten Schulte; Nina Steingrüber; Bernd Jergas; Agnes Redmer; Christina Maria Kurz; Rainer Buchalla; Beat Lutz; Andreas Zimmer; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-04       Impact factor: 3.000

6.  Acetylcholine.

Authors:  David A Brown
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

7.  The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles.

Authors:  Jaromir Myslivecek; Martin Klein; Martina Novakova; Jan Ricny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-29       Impact factor: 3.000

Review 8.  The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease.

Authors:  Philippa R Dale; Hana Cernecka; Martina Schmidt; Mark R Dowling; Steven J Charlton; Michael P Pieper; Martin C Michel
Journal:  Curr Opin Pharmacol       Date:  2014-03-27       Impact factor: 5.547

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.